The downgrade from a 'Strong Buy' to 'Outperform' status, along with a significant reduction in the price target, suggests a less optimistic outlook on QuidelOrtho's stock by Raymond James. This could lead to a negative short-term sentiment among investors, potentially impacting the stock price negatively.